View of SGLT2 inhibitors versus GLP-1 receptor agonists in cardiovascular protection in patients with type 2 diabetes mellitus

Return to Article Details SGLT2 inhibitors versus GLP-1 receptor agonists in cardiovascular protection in patients with type 2 diabetes mellitus Download Download PDF